Immutep LtdASX: IMM

Immutep Quarterly Activities Report and Appendix 4C

· Issued by Immutep Ltd

Filed with ASX · · 12 pages · English

Summary by 6ix AI

The report highlights a strategic collaboration with Dr. Reddy’s for the commercialization of efti, including an upfront payment and potential milestone payments. Immutep reported strong progress in ongoing clinical trials for efti in various cancers, including non-small cell lung cancer and soft tissue sarcoma.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Immutep Ltd on 6ix

Story so far

Earlier from Immutep

Later from Immutep

All Immutep news releases